Comparisons between suicide in persons with serious mental illness, other mental disorders, or no known mental illness: Results from 37 U.S. states, 2003-2017.
Life events
Schizophrenia
Serious mental illness
Suicide
Toxicology
United States
Journal
Schizophrenia research
ISSN: 1573-2509
Titre abrégé: Schizophr Res
Pays: Netherlands
ID NLM: 8804207
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
08
02
2020
revised:
18
08
2020
accepted:
29
11
2020
pubmed:
13
1
2021
medline:
22
6
2021
entrez:
12
1
2021
Statut:
ppublish
Résumé
Suicide is a leading cause of death in persons with schizophrenia and other serious mental illnesses (SMI), however, little is known about the characteristics and circumstances of suicide decedents with SMI in the US compared to those with other or no known mental illness. This study was a retrospective analysis of suicide deaths in individuals aged ≥18 years from the National Violent Death Reporting System, 2003-2017. Odds ratios compared sociodemographic and clinical characteristics, cause of death, precipitating circumstances, and post-mortem toxicology results. All analyses were stratified by gender. Of the 174,001 suicide decedents, 8.7% had a known SMI, 33.0% had other mental disorders, and 58.2% had no known mental illness. Relative to persons with other mental disorders, SMI decedents were younger and more likely to have previous suicide attempts and co-occurring drug use. Problems with intimate partners, poor physical health, and recent institutional release were the most common precipitating circumstances for SMI decedents. Firearms were the most common suicide method for males with SMI. Although 67.0% male and 76.0% of female SMI decedents were currently in treatment, toxicology results suggest many were not taking antipsychotic or antidepressant medications at the time of death. Persons with SMI are over-represented in suicide deaths. Efforts to improve treatment of co-occurring substance use disorders, continuity of care following hospitalization, medication adherence, and to reduce access to firearms are important suicide prevention strategies.
Sections du résumé
BACKGROUND
Suicide is a leading cause of death in persons with schizophrenia and other serious mental illnesses (SMI), however, little is known about the characteristics and circumstances of suicide decedents with SMI in the US compared to those with other or no known mental illness.
METHODS
This study was a retrospective analysis of suicide deaths in individuals aged ≥18 years from the National Violent Death Reporting System, 2003-2017. Odds ratios compared sociodemographic and clinical characteristics, cause of death, precipitating circumstances, and post-mortem toxicology results. All analyses were stratified by gender.
RESULTS
Of the 174,001 suicide decedents, 8.7% had a known SMI, 33.0% had other mental disorders, and 58.2% had no known mental illness. Relative to persons with other mental disorders, SMI decedents were younger and more likely to have previous suicide attempts and co-occurring drug use. Problems with intimate partners, poor physical health, and recent institutional release were the most common precipitating circumstances for SMI decedents. Firearms were the most common suicide method for males with SMI. Although 67.0% male and 76.0% of female SMI decedents were currently in treatment, toxicology results suggest many were not taking antipsychotic or antidepressant medications at the time of death.
CONCLUSIONS
Persons with SMI are over-represented in suicide deaths. Efforts to improve treatment of co-occurring substance use disorders, continuity of care following hospitalization, medication adherence, and to reduce access to firearms are important suicide prevention strategies.
Identifiants
pubmed: 33434737
pii: S0920-9964(20)30648-4
doi: 10.1016/j.schres.2020.11.058
pmc: PMC7987877
mid: NIHMS1658098
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
74-82Subventions
Organisme : NIMH NIH HHS
ID : R01 MH107452
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that we have no conflict of interest.
Références
Medicine (Baltimore). 2016 Jan;95(4):e2475
pubmed: 26825886
J Nerv Ment Dis. 1991 May;179(5):259-66
pubmed: 2022953
Bipolar Disord. 2015 Feb;17(1):1-16
pubmed: 25329791
Am J Psychiatry. 2017 Aug 1;174(8):795-802
pubmed: 28595491
Psychol Med. 2020 May;50(7):1214-1223
pubmed: 31144614
J Affect Disord. 2013 Jul;149(1-3):247-52
pubmed: 23489403
JAMA Psychiatry. 2017 Jul 1;74(7):694-702
pubmed: 28564699
Am J Public Health. 2015 Oct;105(10):2049-58
pubmed: 26270305
Prev Med. 2017 Jul;100:159-166
pubmed: 28455222
Schizophr Res. 2014 May;155(1-3):59-65
pubmed: 24657011
Int J Soc Psychiatry. 2019 Aug;65(5):368-377
pubmed: 31144567
Behav Sci Law. 2019 May;37(3):270-280
pubmed: 31087580
BMC Psychiatry. 2014 Aug 01;14:213
pubmed: 25085220
World Psychiatry. 2011 Feb;10(1):52-77
pubmed: 21379357
Schizophr Bull. 1999;25(3):519-31
pubmed: 10478786
World Psychiatry. 2014 Jun;13(2):153-60
pubmed: 24890068
Int J Geriatr Psychiatry. 2015 Aug;30(8):781-92
pubmed: 25962908
Schizophr Res. 2018 May;195:58-66
pubmed: 28982553
Schizophr Res. 2018 Jul;197:116-123
pubmed: 29395608
World Psychiatry. 2020 Feb;19(1):61-68
pubmed: 31922669
Arch Gen Psychiatry. 2012 May;69(5):476-83
pubmed: 22566579
Transl Psychiatry. 2019 Feb 25;9(1):98
pubmed: 30804323
Bipolar Disord. 2018 Jun;20(4):334-348
pubmed: 29457330
Am J Public Health. 2017 Aug;107(8):1233-1239
pubmed: 28640689
Psychiatry Res. 2015 Aug 30;228(3):791-796
pubmed: 26077849
Arch Suicide Res. 2019 Oct 22;:1-15
pubmed: 31638469
Schizophr Bull. 2018 Jun 6;44(4):787-797
pubmed: 29036388
JAMA Psychiatry. 2016 Nov 1;73(11):1119-1126
pubmed: 27654151
Schizophr Res. 2019 Feb;204:80-89
pubmed: 30253893
Addiction. 2017 Jul;112(7):1250-1259
pubmed: 28192643
Acta Psychiatr Scand. 2018 Nov;138(5):456-463
pubmed: 30076611
Schizophr Res. 2018 Dec;202:347-353
pubmed: 29935885
Eur J Clin Pharmacol. 2019 Oct;75(10):1421-1430
pubmed: 31218371
Psychol Bull. 2017 Feb;143(2):187-232
pubmed: 27841450
Compr Psychiatry. 2011 Sep-Oct;52(5):453-64
pubmed: 21146814
JAMA Psychiatry. 2019 May 1;76(5):508-515
pubmed: 30785609
Bipolar Disord. 2017 Nov;19(7):575-586
pubmed: 28895269
BMJ Open. 2019 Mar 23;9(3):e023883
pubmed: 30904843
Ther Adv Psychopharmacol. 2013 Aug;3(4):200-18
pubmed: 24167693
Aust N Z J Psychiatry. 2020 Jan;54(1):7-9
pubmed: 31852236
Health Aff (Millwood). 2016 Jun 1;35(6):1067-75
pubmed: 27269024
J Psychopharmacol. 2010 Nov;24(4 Suppl):81-90
pubmed: 20923923
Am J Prev Med. 2017 Jul;53(1):130-133
pubmed: 28347589
Psychol Med. 2016 Jan;46(2):225-36
pubmed: 26370729
Inj Prev. 2016 Apr;22 Suppl 1:i6-11
pubmed: 26718549
Ann Epidemiol. 2019 Feb;30:71-73
pubmed: 30578125
J Clin Psychiatry. 2016 May;77(5):661-7
pubmed: 27249075
Schizophr Res. 2001 Mar 1;47(2-3):127-34
pubmed: 11278129
Psychiatr Serv. 2018 Mar 1;69(3):259-267
pubmed: 29191141
Schizophr Res. 2002 Dec 1;58(2-3):253-61
pubmed: 12409166
Acta Psychiatr Scand. 2015 Jun;131(6):417-25
pubmed: 25735195
CNS Spectr. 2018 Aug;23(4):253-263
pubmed: 28535835
Bipolar Disord. 2013 Aug;15(5):457-90
pubmed: 23755739
BMC Psychiatry. 2017 Jan 23;17(1):38
pubmed: 28114913
Schizophr Res. 2013 Nov;150(2-3):416-20
pubmed: 24094723